# Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS

> **NCT05281484** · — · NO_LONGER_AVAILABLE · sponsor: **Clene Nanomedicine**

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** CNM-Au8

## Key facts

- **NCT ID:** NCT05281484
- **Lead sponsor:** Clene Nanomedicine
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05281484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05281484, "Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05281484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*